Mitsubishi Tanabe Lines Up Trials For Hepatitis C Therapy
This article was originally published in PharmAsia News
Executive Summary
TOKYO - As Massachusetts-based Vertex Pharmaceuticals this month launches a closely watched Phase III trial of investigational hepatitis C therapy telaprevir, Osaka-based Mitsubishi Tanabe Pharma has been enrolling Japanese patients for three Phase I/II trials of the drug, an oral protease inhibitor